Cover Image
市場調查報告書

接觸性皮膚炎:開發中產品分析

Contact Dermatitis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 293884
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
接觸性皮膚炎:開發中產品分析 Contact Dermatitis - Pipeline Review, H1 2017
出版日期: 2017年04月11日 內容資訊: 英文 56 Pages
簡介

所謂接觸性皮膚炎是因異物接觸皮膚造成的發炎及過敏反應的一種皮膚炎。症狀是出現紅的皮疹和突疹,乾燥及裂傷的紅斑,有燙傷及疼痛、壓痛般痛感。此外,接觸性皮膚炎有刺激性和過敏性2種,最常見的有接觸酸性物質,肥皂和洗滌清潔劑,柔軟劑,溶劑的鹼性物質,及其他的化學物質所引起的類型,接觸後的反應類似燙傷。過敏性則是敏感性肌膚對過敏原產生過敏反應。治療可使用口服皮質類固醇和抗組織胺藥物來緩解症狀。

本報告提供接觸性皮膚炎的治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等資訊,為您概述為以下內容。

目錄

簡介

接觸性皮膚炎概要

治療藥的開發

  • 開發中產品:概要
  • 開發中的治療藥:各企業
  • 開發中的產品:各企業

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Anacor Pharmaceuticals Inc
  • AskAt Inc
  • Brickell Biotech Inc
  • Dr. August Wolff GmbH & Co KG Arzneimittle
  • Edesa Biotech Inc
  • Hapten Sciences Inc
  • ILiAD Biotechnologies LLC
  • Marinomed Biotechnologie GmbH
  • Novartis AG
  • Signum Dermalogix Inc

藥物簡介

暫停中的企劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9173IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Contact Dermatitis - Pipeline Review, H1 2017, provides an overview of the Contact Dermatitis (Dermatology) pipeline landscape.

Contact dermatitis is a type of skin inflammation that occurs when substances touching skin cause irritation or an allergic reaction. Signs and symptoms of contact dermatitis include red rash or bumps, dry, cracked, red patches, which may resemble a burn and pain or tenderness. There are two types of contact dermatitis; irritant and allergic. Irritant dermatitis, the most common type, is caused by contact with acids, alkaline materials such as soaps and detergents, fabric softeners, solvents, or other chemicals. The reaction usually looks like a burn. Allergic contact dermatitis is an itchy skin condition caused by an allergic reaction to allergen. Treatment includes oral corticosteroids and antihistamines to relieve intense itching.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Contact Dermatitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Contact Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Contact Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Contact Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 3 and 7 respectively.

Contact Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Contact Dermatitis (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Contact Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Contact Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Contact Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Contact Dermatitis (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Contact Dermatitis (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Contact Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Contact Dermatitis - Overview
    • Contact Dermatitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Contact Dermatitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Contact Dermatitis - Companies Involved in Therapeutics Development
    • Anacor Pharmaceuticals Inc
    • AskAt Inc
    • Brickell Biotech Inc
    • Dr. August Wolff GmbH & Co KG Arzneimittle
    • Edesa Biotech Inc
    • Hapten Sciences Inc
    • ILiAD Biotechnologies LLC
    • Marinomed Biotechnologie GmbH
    • Novartis AG
    • Signum Dermalogix Inc
  • Contact Dermatitis - Drug Profiles
    • AAT-008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AN-3485 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BBI-2000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • beta-escin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EB-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EB-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • grapiprant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HPT-721 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pertussis [strain BPZE1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • secukinumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SIG-1322 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WOL-071007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Contact Dermatitis - Dormant Projects
  • Contact Dermatitis - Discontinued Products
  • Contact Dermatitis - Product Development Milestones
    • Featured News & Press Releases
      • Nov 19, 2015: Hapten Sciences to Begin Clinical Trials for Novel Poison Ivy Vaccine
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Contact Dermatitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Contact Dermatitis - Pipeline by Anacor Pharmaceuticals Inc, H1 2017
  • Contact Dermatitis - Pipeline by AskAt Inc, H1 2017
  • Contact Dermatitis - Pipeline by Brickell Biotech Inc, H1 2017
  • Contact Dermatitis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H1 2017
  • Contact Dermatitis - Pipeline by Edesa Biotech Inc, H1 2017
  • Contact Dermatitis - Pipeline by Hapten Sciences Inc, H1 2017
  • Contact Dermatitis - Pipeline by ILiAD Biotechnologies LLC, H1 2017
  • Contact Dermatitis - Pipeline by Marinomed Biotechnologie GmbH, H1 2017
  • Contact Dermatitis - Pipeline by Novartis AG, H1 2017
  • Contact Dermatitis - Pipeline by Signum Dermalogix Inc, H1 2017
  • Contact Dermatitis - Dormant Projects, H1 2017
  • Contact Dermatitis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Contact Dermatitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top